Peptide Briefs

  • Peptide Briefs Weekly Top 10: Week of Nov 6, 2026

    Peptide Briefs Weekly Top 10: Week of Nov 6, 2026

    Originally pusblished on Substack

    This week’s new material: labs returning very different numbers on what was reported as the same product, a telehealth company staging a peptide line, warnings of shipping delays ahead of the Shenzhen summit, and tighter customs scrutiny. The HHS peptide policy we covered last week is a follow-up, further down. Ten items follow, with what the evidence does and does not show. Nothing here is medical advice or a recommendation to use any compound.

    SUBSCRIBE

    1. Same sample, different labs, very different numbers

    Krysia, who writes a Substack that digs into third-party peptide testing, documented several cases this week where labs disagreed on the same product. The credit for surfacing these goes to her work and to the labs willing to publish their results. These are anecdotal, vendor-submitted samples, not controlled comparisons, and separate vials can differ. In one case, described as apparently the same batch of a 10 mg retatrutide product, one lab reported 3.98 mg at 36.44% purity, a second reported about 7.7 mg at about 67.3% (two runs, 67.301% and 67.319%), and a third reported 11.26 mg at 98.183%. Janoshik said the simplest explanation for its gap with the second lab was “sample difference”; the first lab declined to discuss. In another case, two labs tested separate vials from the same 10 mg eloralintide kit: one reported 99.74% purity and 10.09 mg, the other 67.8% and 12.1 mg. The second lab stands by its result, citing an extra chromatogram peak that barely registered at 220 nm but showed strongly at 280 nm, which it says it has not yet identified; it says it ruled out two candidate explanations, and no response from the first lab was available. Methods also differ in what “purity” means: one lab does not report blend purity at all because overlapping peaks can hide impurities, another reports combined peak area and says it is “not absolute mass purity,” and one lab found the TB-500 fragment co-eluted with another component. The takeaway: “99%” on a certificate usually means 99% of detected peak area at one wavelength, not 99% of the vial, and a single certificate cannot settle quality. A separate site reports several popular labs are not accredited (ISO/IEC 17025) for peptide assays; it has vendor ties, so verify before citing.

    Sources: Krysia (Substack) and her follow-up notes, ChemVerify (commercial ties)

    2. Telehealth moves in: Hims & Hers stages a peptide line

    On its Aug 10 earnings call, Hims & Hers said it planned to sell compounded peptides by the end of 2026 in phases: sermorelin, glutathione and an existing product first, and the six committee-recommended peptides only after FDA action. The day after HHS acted, its Oct 29 release described a “Peptides+” preview with a waitlist, listing sermorelin, glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 to follow “when allowable.” The release gives no launch date or pricing, says treatment would come through independent providers and licensed pharmacies, and itself notes that published studies are limited. Becker’s reports the company is running stability testing on BPC-157 at a California facility. As of this week, this is a waitlist and a plan, not a launch.

    Sources: Hims & Hers release (company, promotional), Becker’s Hospital Review

    3. Shenzhen summit: shipping delays are warned, but no export restriction is confirmed

    The APEC Economic Leaders’ Meeting is scheduled for Nov 18 to 19 in Shenzhen. A peptide sourcing vendor’s advisory says freight partners expect “enhanced security measures and stricter cargo inspections” in Shenzhen-area logistics hubs before and during the summit, with delays it calls impossible to predict. That advisory does not mention any government restriction on peptide exports, and I found no confirmed Chinese government export restriction on peptides. Separate social posts relay vendor warnings of a longer shipping disruption starting in late September; I could not verify those. Treat this as a logistics warning, not a policy change.

    Sources: APEC China 2026 (Wikipedia), vendor advisory (commercial source)

    4. Customs and enforcement are tightening on peptide shipments

    On Nov 5, NL Times (citing RTL Nieuws and BNR) reported that Dutch Customs stopped “hundreds of shipments” containing peptides through September, mostly by courier, while RTL identified 203 illegal online pharmacies, more than half under six months old, with products mainly supplied from China. Earlier this year, U.S. Customs and Border Protection reported a Cincinnati interdiction of roughly 5,000 mis-manifested peptide shipments from China, per a secondary summary of the CBP release (exact dates should be confirmed against the primary release). Neither report describes Chinese export controls.

    Sources: NL Times, ChemVerify (secondary, commercial ties)

    5. A large preprint finds wide variability in marketed research peptides

    A preprint by Mendias and Awan (Apr 24, 2026; not peer reviewed) analyzed public third-party testing data from Finnrick Analytics: 14 peptides, 6,285 analyzed samples from 203 companies, tested between December 2024 and April 2026. Depending on the acceptance standard, 41.6% to 71.1% of samples failed basic criteria. Median measured content was 101.8% of label claim, but TB-500 had the lowest median purity (97.29%) and the highest identity failure rate (10.0%), and quality varied more between vendors than between peptides. Endotoxin data existed for under 4% of samples, and 15% of those showed measurable endotoxin. The authors caution the data are voluntary submissions, not a representative sample, and the failure rates are likely a lower bound.

    Source: Preprints.org 202604.1748

    6. A new orthopaedic review: preclinical promise, thin human data

    A narrative review in the Journal of the American Academy of Orthopaedic Surgeons (online Oct 27) covers BPC-157, thymosin beta-4 and TB-500, searching PubMed, EMBASE and Scopus through June 2026. BPC-157 has the largest musculoskeletal preclinical literature, mostly in small animals, while the human musculoskeletal evidence is one small, retrospective, uncontrolled case series. Thymosin beta-4’s musculoskeletal evidence is in vitro and rodent only, and TB-500 is a seven-amino-acid fragment often confused with full-length thymosin beta-4, with no validated equivalence. The authors flag identity, purity, sterility and consistency concerns for commercial products and conclude routine clinical use cannot currently be recommended.

    Source: PubMed 42937313

    7. Follow-up: the HHS interim policy on six peptides, one week on

    As covered last week, the Department of Health and Human Services filed an interim policy on Oct 28 (scheduled for Federal Register publication Oct 30) covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound these six while FDA works on its 503A bulks list. The policy is interim and non-final, signed by the HHS Secretary rather than issued by FDA, and HHS says it may revisit it if a safety signal or quality problem appears.

    Sources: AJMC, Foley & Lardner

    8. What the policy requires, and what it is not

    Per a law-firm summary, enforcement discretion applies only if conditions are met: the bulk substance comes from an FDA-registered facility with a valid certificate of analysis, the original manufacturer is FDA-registered and CGMP-compliant, adverse events go to MedWatch, the product has a single active ingredient, and labeling states “This is a compounded drug product. Not for resale.” The policy does not add the peptides to the 503A bulks list and is not FDA approval of any compounded product. A formal listing would need notice-and-comment rulemaking, which can take months to years. FDA does not review compounded products for safety, effectiveness or quality before marketing.

    Sources: Foley & Lardner, BioXconomy

    9. The policy departs from FDA staff advice, and a petition pushes back

    In July, FDA’s Pharmacy Compounding Advisory Committee narrowly recommended six of seven nominated peptides after the panel was reshaped; some members reportedly had industry ties. FDA’s career scientists recommended against, citing poorly characterized structures, limited safety data, contamination risk, possible immune reactions from peptide aggregation and little data on combinations. HHS says circumstances changed and calls CDER’s concerns “inferential/mechanistic rather than based on observed harm,” but as of BioXconomy’s reporting the evidence HHS cited had not been published. The Partnership for Safe Medicines petitioned FDA (reported Oct 26) to disregard the vote. Written comments on the HHS policy are due two weeks after publication, which one law-firm summary puts at Nov 13.

    Sources: pharmaphorum, BioXconomy, AJMC, PeptideLaws

    10. Approved peptide drugs keep moving: NICE expands Imcivree, GLP-1 pipeline advances

    Rhythm Pharmaceuticals announced Nov 4 that NICE issued positive guidance for Imcivree (setmelanotide) for adults with genetically confirmed Bardet-Biedl syndrome in England, Wales and Northern Ireland, expanding a May 2024 recommendation for ages 6 to 17; children 2 to 5 are already funded through NHS England. This comes from a company press release that says it is intended for investors, cites no trial numbers and does not quote NICE, so check NICE’s own document. It is a regulated drug for a rare genetic condition, a contrast with the unapproved research peptides above. On incretins, per an industry aggregator (check primary sources), retatrutide’s TRIUMPH-2 showed 20.8% weight loss at 80 weeks on 12 mg versus 4.0% on placebo, with Lilly targeting a filing in Q1 2027; survodutide’s SYNCHRONIZE-2 reported 13.1% versus 3.1% at 76 weeks; orforglipron has a positive CHMP opinion with the European Commission decision pending.

    Sources: Rhythm Pharmaceuticals release (company), Life Science Daily

    Dates to watch: Nov 13 (HHS comment deadline, per one law-firm summary), Nov 14 to 17 (ObesityWeek), Nov 18 (NICE orforglipron appraisal expected), Nov 18 to 19 (APEC Shenzhen). No published date: FDA’s CagriSema decision and any bulks-list rulemaking.

    Evidence note: Items 2 to 4 and 7 to 9 are policy, business and logistics reporting; item 1 is anecdotal, not evidence about whether these compounds work. Item 6 is the only peer-reviewed abstract verified this week; item 5 is a preprint. Company press releases are labeled as promotional.

    Credits: item 1 draws on Krysia’s Substack reporting and the lab results she compiled (Janoshik, Freedom Diagnostics, Chromate, BT Labs, Vanguard, Testides, Amino Metrics). Item 5 is the work of Mendias and Awan using public data from Finnrick Analytics. Item 6 is the JAAOS review authors’ work. Item 2 draws on Hims & Hers’ own release and Becker’s Hospital Review. Item 4 draws on NL Times (reporting by RTL Nieuws and BNR). Items 7 to 9 draw on AJMC, Foley & Lardner, BioXconomy, pharmaphorum and PeptideLaws.

  • The FDA’s Six, Part Two: a peptide policy is sitting at the White House. Here’s what it would and wouldn’t change.

    The FDA’s Six, Part Two: a peptide policy is sitting at the White House. Here’s what it would and wouldn’t change.

    Find Part One Here

    On October 14, HHS and the FDA sent a document called “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Management and Budget for review. It is listed as pending. Reuters reported the submission the next day, and within 48 hours several headlines had the FDA “fast-tracking” peptides.

    It isn’t. Here is what actually happened, what the document most likely says, and what it cannot do.

    Where this came from:

    In September we covered what the human evidence shows for the six peptides an FDA advisory committee voted toward the compounding list in July: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. Short version: all six sit at C on our scale. Cell and animal data, little or no controlled human data, and in several cases no published human trial at all.

    The votes were close and they went against the agency’s own scientists. FDA staff had recommended against all seven peptides under review on June 29, citing poorly characterized substances, limited human data and immune-reaction risk. BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention. Emideltide (DSIP) failed 6 to 7. Roughly half the reconstituted committee was reported to have ties to peptide clinics or businesses.

    A committee vote does not put anything on the 503A bulks list. That takes a proposed rule, a comment period and a final rule. The last time FDA did this for a batch of ten substances, the proposed rule came in 2016 and the final rule in 2019.

    What the October 14 document most likely is

    Nobody outside government has read it. But the title says “interim” and “access,” and the FDA already runs an interim policy for nominated bulk substances. Under that policy, a substance in Category 1 can be compounded by a state-licensed 503A pharmacy while the agency keeps evaluating it, because the FDA says it does not intend to enforce against that use. Category 2 substances, where BPC-157 and friends sat from 2023 until April of this year, get no such discretion.

    So the most likely shape is this: the six move into Category 1, with conditions. A prescriber writes a prescription for one patient. A licensed pharmacy compounds it from bulk material that meets whatever sourcing and testing standards the policy names. The FDA agrees not to pursue that pharmacy for it, for now.

    What it would not do

    1. It would not approve anything. Enforcement discretion is the agency saying what it will not prosecute. The peptides would remain unapproved drugs with the same evidence base they have today.
    2. It would not be permanent. A guidance document can be narrowed or withdrawn without a comment period. The compounded semaglutide and tirzepatide discretion periods ended the same way.
    3. It would not cover products sold as research chemicals, dietary supplements or through 503B outsourcing facilities. The channel it opens is prescription-only, through a pharmacy.
    4. It would not bind state pharmacy or medical boards, which can still say no.
    5. It could be limited by route. Some committee members tied their yes votes to specific routes of administration, and the policy could follow them.

    That third point deserves a second look, because it is the one the headlines skip.

    The other half of the story

    While the access story got the attention, enforcement went the other way. On August 24 the FDA sent five warning letters to online peptide vendors. The agency’s reasoning is worth knowing exactly: a “research use only” label did not outweigh evidence the products were intended for people, and the evidence it pointed to was bacteriostatic water sold for mixing and dosing calculators offered alongside the vials.

    On September 18 a warning letter went to a compounder whose GLP-1 products with added B12 or niacinamide were, in the FDA’s view, essentially copies of approved drugs. The same letter questioned prescriptions generated from preselected menu options on telehealth platforms. And in August the developer of retatrutide filed six lawsuits against sellers and reported more than 200 referrals to regulators.

    Read those two threads together. The administration is building a narrow, licensed, prescription path for six C-grade peptides, and at the same time the agency is telling the gray market that the label on the vial is not a defense if the rest of the website says otherwise.

    What happens next

    Date

    What

    Now

    OMB review of the interim policy; no deadline, no public text

    Before end of Feb 2027

    Second advisory committee meeting on GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF; date not set

    2027

    A proposed rule for the bulks list, if FDA accepts the July votes

    Late 2027 to 2028

    A final rule, on the 2016-to-2019 precedent

    Jan 2029

    Whatever survives the 2028 election

    If the policy comes out, the things to read first are the conditions: which lab standards the bulk material has to meet, whether the FDA-registered facility and certificate-of-analysis language applies, and whether any route is excluded. Those conditions will say more about where this is going than the headline.

    What it means for the grades

    Nothing. A grade here is a statement about evidence, and no evidence changed this month. Access and evidence are different questions, and a policy that opens the first does not answer the second. If a controlled human trial of any of the six publishes, you will read about it here, and the grade will move then.

    The six pages, for reference: BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax.

    Disclosure: I co-own a research-peptide vendor. That is stated on every page here, and this library does not link to it.

    Peptide Briefs is an independent reference. Nothing here is medical advice or a recommendation to use any compound.

    Also published on Substack

  • The FDA’s Six: What the Human Evidence Actually Shows

    On July 23-24, 2026, something unusual happened at the FDA’s White Oak campus. The Pharmacy Compounding Advisory Committee, a panel that exists to give the agency outside expert advice, voted against FDA staff’s own written recommendations six times in a row. Reporters in the room described an audible gasp when the first tally was read.

    The result: BPC-157, TB-500, Semax, KPV, MOTS-c, and Epitalon all received committee recommendations for inclusion on the FDA’s 503A Bulks List, the mechanism that lets licensed compounding pharmacies legally prepare patient-specific prescriptions. A seventh compound, Emideltide (DSIP), was voted down.

    This is not FDA approval. It’s not even a final decision. It’s a non-binding recommendation, and as of this writing, two months later, the FDA hasn’t acted on it. Formal rulemaking, if it happens, typically takes 8-12 months.

    But the vote raises a question worth answering properly: what does the actual human evidence say about these six compounds? Not the mechanism papers, not the mouse studies people cite as if they settle the matter. The human data specifically. Here’s the honest picture, compound by compound.

    BPC-157

    Grade: D. Plausible mechanism, essentially no human evidence.

    BPC-157 has zero completed human randomized controlled trials. That’s the single fact that matters most here, and it’s worth sitting with before anything else.

    The closest thing to human-scale data is a recent retrospective count of 1,039 documented users, tracked from nadir to follow-up. That’s a real number, but it measures something different than most people assume: it tells you how many people used the compound, not whether it worked. A usage count and an efficacy result are two different questions, and conflating them is the most common error in how this compound gets discussed.

    The clinical history is also more instructive than most coverage lets on. The original research trail goes back to PLIVA, the Croatian pharmaceutical company that worked with discoverer Predrag Sikiric. PLIVA registered early-stage trials around 2000 that were never published. The research was sold to GSX in 2006, and GSX abandoned it. A separate trial in Tijuana in 2015 was also canceled with no data released. Multiple companies with real resources picked this compound up and walked away. That’s a different story than “suppressed because it works,” but it’s also not nothing.

    TB-500

    Grade: D. Same evidence category as BPC-157.

    TB-500 (a synthetic fragment of Thymosin Beta-4) has an extensive preclinical literature on tissue repair, cell migration, and wound healing. None of it has translated into a completed human clinical trial for the injectable research compound as it’s commonly sold.

    The mechanistic story is genuinely interesting; it’s thought to coordinate the movement of cells involved in tissue repair, which is why it shows up so often in sports medicine and regenerative medicine discussions. But “mechanistically interesting” and “shown to work in humans” remain two separate claims, and only the first one currently has support.

    Semax

    Grade: D, with an asterisk worth understanding.

    Semax has a real research history, just not one that shows up cleanly in a PubMed search. A meaningful share of the literature on Semax (and several other Russian-developed compounds, including some of the older bromantane and actovegin research) exists in Russian-language journals that were never translated or indexed in the databases most Western researchers default to.

    This matters because “no human trials” and “no human trials I can find in English” are different claims, and the discourse around Semax tends to treat them as identical. To be direct about the limits of this caveat: this is a well-documented pattern in the space, and it’s a real gap in how evidence gets surfaced, but it isn’t a claim we’ve personally verified paper-by-paper. Treat it as an important qualifier, not a settled fact that resolves the evidence question in Semax’s favor.

    KPV

    Grade: D. The strongest mechanism of the six, and still zero completed human trials.

    KPV is a three-amino-acid fragment of alpha-MSH, and its mechanism is unusually well-characterized for a compound this size. It enters intestinal and immune cells through the PepT1 transporter, the same carrier that handles dipeptides and tripeptides from digested dietary protein, and once inside, it interferes with the importin-alpha3/p65RelA complex, blocking NF-kB nuclear translocation and suppressing downstream inflammatory cytokines (TNF-alpha, IL-1, IL-6).

    The animal data is genuinely strong: DSS and TNBS mouse colitis models (Dalmasso 2008, Kannengiesser 2008) show meaningful reductions in inflammatory markers. The problem is the translation step. DSS/TNBS mouse colitis models have historically translated to human outcomes at only 10-15%, a sobering number for any compound whose entire efficacy case currently rests on mouse data. Zero completed human RCTs exist for KPV in any indication.

    MOTS-c

    Grade: D. The clearest correlation-vs-causation trap of the six.

    MOTS-c is a 16-amino-acid peptide encoded directly in mitochondrial DNA, discovered in 2015. The animal data (primarily mice) shows real effects on insulin sensitivity, inflammatory markers, and glucose homeostasis.

    The human data that exists is purely observational: exercise increases circulating MOTS-c levels in skeletal muscle and blood. That’s a real finding, but it’s a correlation between exercise and a biomarker, not a controlled trial testing whether giving someone exogenous MOTS-c produces a treatment effect. No published human interventional trial has tested that question. The gap between “your body makes more of this when you exercise” and “taking more of this replicates exercise’s benefits” is exactly the kind of gap that’s easy to paper over with hopeful language, and worth naming directly instead.

    Epitalon

    Grade: D. Same literature-access problem as Semax.

    Epitalon carries a near-legendary reputation in longevity circles, and its research history runs into the same issue as Semax: a real body of work exists, much of it Russian in origin, and much of it sits outside what’s easily searchable in English-language databases. The same caveat applies here as it did for Semax: this is a documented pattern worth naming, not a fully verified claim that resolves the evidence gap.

    The pattern across all six

    Every one of these compounds has a plausible, often well-characterized mechanism. Every one has real preclinical (mostly animal) data supporting that mechanism. And every one is missing the thing that actually determines whether a compound works in people: a completed human clinical trial.

    That’s not a condemnation of any of them. Plenty of compounds with this exact profile eventually clear that bar. It’s just the honest state of the evidence right now, and it’s worth being precise about it independent of the regulatory news cycle.

    Here’s the distinction that matters most going forward: a 503A compounding recommendation, if the FDA eventually adopts it, changes the legal pathway for these compounds. It does not change the evidence. Those are two separate axes, and it’s worth not letting a genuinely significant regulatory story get mistaken for a medical one.

    We’ll keep grading these as the literature moves. If any of the six clears a real human trial, that’s the post that follows this one.